Series

Molecules and Aging

Aging is not one thing. Many molecular clocks are running at once.

This series takes a molecular-biology view, examining one mechanism at a time: a map of the aging framework; Taiwanese data on plasma proteins and mortality prediction; the gap between animal and human evidence for clearing senescent cells; and what the first human trial of epigenetic reprogramming is actually testing. Each article asks the same question: how far does the science go, and how far have the claims run ahead?

The Twelve Hallmarks of Aging: A Map, Not a PrescriptionA full reading of the 2023 framework of twelve hallmarks of aging: evidence strength differs for each, moving from animals to people requires conditions, and “improving one hallmark prevents aging” skips necessary steps. (Start here.)
Can Plasma Proteins Predict Who Dies First? Answers from 848 People Followed for Eight and a Half Years in TaiwanA National Yang Ming Chiao Tung University and Taipei Veterans General Hospital team followed 848 people for 8.5 years and built a plasma-proteome mortality-prediction score. Its C-index was 0.81, but the external-validation sample was small. Predictive power and causal inference are different things.
Senolytics: Between the Longevity Numbers in Mice and the Supplement in Your CabinetClearing senescent cells extended mouse lifespan by 24–27%, but human trials use single-disease endpoints, are small, and do not test lifespan. SASP has beneficial functions too, while the regulatory path for fisetin and quercetin has become detached from this scientific context.
Where Should Reprogramming Stop: OSK's First Human Trial Isn't Treating AgingThe first human trial of partial epigenetic reprogramming treats glaucoma and ischemic optic neuropathy; all 22 primary endpoints concern safety. Animal evidence runs on three lines, and the often cited “+109% remaining lifespan” becomes +7% when the denominator changes.

Further reading

Subscribe to new posts